<DOC>
	<DOCNO>NCT01354977</DOCNO>
	<brief_summary>The purpose research study effect medication call resveratrol body 's response insulin ( hormone control blood sugar ) , inflammation and/or specific cell process fat tissue , skeletal muscle metabolism brain function .</brief_summary>
	<brief_title>Effect Resveratrol Age-related Insulin Resistance Inflammation Humans</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<criteria>BMI : 2635 Nonsmoker Normal screen lab ( CMC , chemistry , LFTs PT/PTT ) No CAD Good IV access High cholesterol &lt; 4 week history participation another drug trial Severe hypertension Heart disease Liver disease liver abnormalities Cerebrovascular disease , i.e . stroke CVD Seizures Bleeding disorder Muscle disease Cancer HIV Hepatitis ( type ) Mentally disabled person Pregnant woman Allergies Novocaine , Lidocaine , Benzocaine Subjects follow medication : Anticoagulant antiplatelet drug Antiepileptic drug Mexiletene Quinidine Cyclosporine Tacrolimus HIV protease inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Endocrin System Diseases</keyword>
	<keyword>Resveratrol</keyword>
	<keyword>Therapeutic Uses</keyword>
</DOC>